speb/financial-data huggingface dataset:
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Other Non Cash Items: -10043900000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Non Current Assets: 5401200000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 5401200000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Non Current Liabilities: 191800000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: 191800000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Other Non Operating Income Expenses: 863400000.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 6128700000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Other Operating Expenses: 48730300000.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 44082800000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Payable: 18405200000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Payable: 18405200000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Properties: 100359400000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Properties: 100359400000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Receivables: -207300000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Receivables: -207300000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Short Term Investments: 160488700000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 160488700000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Other Special Charges: 3095300000.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Other Special Charges: -66400000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Payables: 80397700000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Payables: 80397700000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 7186400000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 7186400000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Prepaid Assets: 28491100000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 28491100000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Pretax Income: 137521300000.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Pretax Income: 32543500000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Properties: 0.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Provisionand Write Offof Assets: 1808300000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Purchase Of Business: -2728300000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Purchase Of Investment: -345152100000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Purchase Of PPE: -21285800000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Raw Materials: 36502400000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Raw Materials: 36502400000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Reconciled Cost Of Revenue: 121975100000.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 26371900000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Reconciled Depreciation: 25753900000.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 6637900000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Rent And Landing Fees: 777400000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Rent Expense Supplemental: 777400000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Repayment Of Debt: -43438400000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Repurchase Of Capital Stock: -28998500000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Restricted Cash: 200000000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Restricted Cash: 200000000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Restructuring And Mergern Acquisition: 1013800000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Retained Earnings: 578618400000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Retained Earnings: 578618400000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Sale Of Business: 0.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Sale Of Investment: 306510600000.00
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Sale Of PPE: 610100000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Selling And Marketing Expense: 65768600000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Selling General And Administration: 103004500000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Share Issued: 2399334970.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Share Issued: 2399334970.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Special Income Charges: -7133400000.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Special Income Charges: -3616800000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Stockholders Equity: 722180200000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 722180200000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Tangible Book Value: 542580600000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 542580600000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Tax Effect Of Unusual Items: -335837370.87
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: -1215520865.30
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Tax Provision: 27720300000.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Tax Provision: 10937100000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Tax Rate For Calcs: 0.20
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.34
SUNPHARMA.NS cash_flow (annual, 2025-03-31) — Taxes Refund Paid: -4768400000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Assets: 921005800000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Assets: 921005800000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Capitalization: 722205400000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 722205400000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Debt: 23621900000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Debt: 23621900000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Equity Gross Minority Interest: 724859500000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 724859500000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Total Expenses: 394600500000.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Total Expenses: 100545200000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Liabilities Net Minority Interest: 196146300000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 196146300000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Non Current Assets: 394761100000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 394761100000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 14204200000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 14204200000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Tax Payable: 7331800000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 7331800000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Total Unusual Items: -1666100000.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items: -3616800000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Total Unusual Items Excluding Goodwill: -1666100000.00
SUNPHARMA.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: -3616800000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Tradeand Other Payables Non Current: 87600000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Tradeand Other Payables Non Current: 87600000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Work In Process: 20192300000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Work In Process: 20192300000.00
SUNPHARMA.NS balance_sheet (annual, 2025-03-31) — Working Capital: 344302600000.00
SUNPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Working Capital: 344302600000.00
SUNPHARMA.NS income_statement (annual, 2025-03-31) — Write Off: 2953000000.00
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — +Operating Expense: 75992400000.00
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — +Total Revenue: 137860700000.00
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Basic Average Shares: 2398557895.00
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Basic EPS: 9.50
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 28147600000.00
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 7005500000.00
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Depreciation Income Statement: 7005500000.00
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 2398557895.00
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Diluted EPS: 9.50
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 22786300000.00
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — EBIT: 32475700000.00
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — EBITDA: 39481200000.00
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Gross Profit: 109713100000.00
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Interest Expense: 748000000.00
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 748000000.00
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Minority Interests: -142400000.00
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income: 22786300000.00
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 22786300000.00
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 22928700000.00
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 22786300000.00
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 22786300000.00
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 22928700000.00
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Interest Income: -748000000.00
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -748000000.00
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 47661200000.00
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Normalized Income: 28722889037.34
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Operating Income: 33720700000.00
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Operating Revenue: 137860700000.00
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 4644600000.00
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 41623600000.00
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Otherunder Preferred Stock Dividend: 0.00
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Pretax Income: 31727700000.00
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 28147600000.00
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 7005500000.00
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Special Income Charges: -8180000000.00
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: -2243410962.66
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Tax Provision: 8701500000.00
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.27
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Total Expenses: 104140000000.00
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items: -8180000000.00
SUNPHARMA.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: -8180000000.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — +Operating Expense: 84617300000.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — +Total Revenue: 154690700000.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Basic Average Shares: 2406292857.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Basic EPS: 14.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 29451000000.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 7323300000.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Depreciation Income Statement: 7323300000.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 2406292857.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Diluted EPS: 14.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 33688100000.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — EBIT: 43055200000.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — EBITDA: 50378500000.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Gross Profit: 125239700000.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Interest Expense: 783600000.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 783600000.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Minority Interests: -123600000.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income: 33688100000.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 33688100000.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 33811700000.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 33688100000.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 33688100000.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 33811700000.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Interest Income: -783600000.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -783600000.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 55273300000.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Normalized Income: 37626360045.04
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Operating Income: 40622400000.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Operating Revenue: 154690700000.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 5788400000.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 48888700000.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Other Special Charges: 4894800000.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Pretax Income: 42271600000.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 29451000000.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 7323300000.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Special Income Charges: -4894800000.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: -956539954.96
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Tax Provision: 8260700000.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.20
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Total Expenses: 114068300000.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items: -4894800000.00
SUNPHARMA.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: -4894800000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — +Operating Expense: 314521500000.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — +Operating Expense: 90066800000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — +Total Revenue: 582201100000.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — +Total Revenue: 145597500000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Accounts Payable: 73338000000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 73338000000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Accounts Receivable: 155096700000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 155096700000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Accumulated Depreciation: -155152700000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Accumulated Depreciation: -155152700000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Additional Paid In Capital: 11881600000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 11881600000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Allowance For Doubtful Accounts Receivable: -2924100000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Allowance For Doubtful Accounts Receivable: -2924100000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Amortization: 15666500000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Amortization Cash Flow: 15666500000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Assets Held For Sale Current: 309000000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Assets Held For Sale Current: 309000000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Available For Sale Securities: 26686700000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Available For Sale Securities: 26686700000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Basic Average Shares: 2401552301.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Basic Average Shares: 2401796460.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Basic EPS: 47.80
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Basic EPS: 11.30
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Beginning Cash Position: 102687700000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Buildings And Improvements: 80743300000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Buildings And Improvements: 80743300000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Capital Expenditure: -36093700000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Capital Lease Obligations: 5457100000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 5457100000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Capital Stock: 2399300000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Capital Stock: 2399300000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Cash And Cash Equivalents: 97705100000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 97705100000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 337814600000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 337814600000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Cash Dividends Paid: -39339000000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Cash Equivalents: 42694800000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Cash Equivalents: 42694800000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Cash Financial: 55010300000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Cash Financial: 55010300000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Inventory: -523000000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Other Current Assets: -2095600000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Other Current Liabilities: 1754100000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Payable: 10573800000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Receivables: -20087600000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Working Capital: -12677900000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Changes In Cash: -14374200000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Common Stock: 2399300000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Common Stock: 2399300000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Common Stock Equity: 835700900000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 835700900000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Common Stock Payments: -38000000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Construction In Progress: 15232100000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Construction In Progress: 15232100000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Cost Of Revenue: 131731400000.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 28010900000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Assets: 638911900000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Assets: 638911900000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Capital Lease Obligation: 1840800000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 1840800000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Debt: 40503500000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Debt: 40503500000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Debt And Capital Lease Obligation: 42344300000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 42344300000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Deferred Taxes Liabilities: 13500400000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Deferred Taxes Liabilities: 13500400000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Liabilities: 226220400000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 226220400000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Provisions: 48452000000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Provisions: 48452000000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Depreciation: 13712000000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Depreciation And Amortization: 29378500000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Depreciation And Amortization In Income Statement: 29378500000.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 7754700000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Depreciation Income Statement: 13712000000.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Depreciation Income Statement: 7754700000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Diluted Average Shares: 2401552301.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 2401796460.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Diluted EPS: 47.80
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Diluted EPS: 11.30
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Diluted NI Availto Com Stockholders: 114794200000.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 27140300000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Dividends Payable: 179800000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Dividends Payable: 179800000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Dividends Received Cfi: 594000000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — EBIT: 154577900000.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — EBIT: 36372300000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — EBITDA: 183956400000.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — EBITDA: 44127000000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Effect Of Exchange Rate Changes: 7764300000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — End Cash Position: 97705100000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 4719200000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 4719200000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Financing Cash Flow: -25125500000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Finished Goods: 51925800000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Finished Goods: 51925800000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Free Cash Flow: 88098100000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Gain Loss On Investment Securities: -9355000000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Gain Loss On Sale Of Business: 0.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Gain Loss On Sale Of PPE: 1772800000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — General And Administrative Expense: 37291700000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Goodwill: 98330800000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Goodwill: 98330800000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Goodwill And Other Intangible Assets: 233792400000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 233792400000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Gross Accounts Receivable: 158020800000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Gross Accounts Receivable: 158020800000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Gross PPE: 281525900000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Gross PPE: 281525900000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Gross Profit: 450469700000.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Gross Profit: 117586600000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Hedging Assets Current: 176900000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Hedging Assets Current: 176900000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Impairment Of Capital Assets: 1708300000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Interest Expense: 3389100000.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Interest Expense: 858900000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Interest Expense Non Operating: 3389100000.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 858900000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Interest Income: 9150000000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Interest Income Non Operating: 9150000000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Interest Paid Cff: -3314600000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Interest Received Cfi: 7046600000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Inventory: 114929300000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Inventory: 114929300000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Invested Capital: 876517000000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Invested Capital: 876517000000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Investing Cash Flow: -113440500000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Investmentin Financial Assets: 31405900000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Investmentin Financial Assets: 31405900000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Investmentsin Associatesat Cost: 6111800000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Investmentsin Associatesat Cost: 6111800000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Investmentsin Joint Venturesat Cost: 400400000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Investmentsin Joint Venturesat Cost: 400400000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Issuance Of Debt: 52021500000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Land And Improvements: 11899400000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Land And Improvements: 11899400000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Long Term Capital Lease Obligation: 3616300000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 3616300000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Long Term Debt: 312600000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 312600000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 3928900000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 3928900000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Long Term Debt Issuance: 52021500000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Long Term Debt Payments: -34101900000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Long Term Equity Investment: 6512200000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Long Term Equity Investment: 6512200000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Long Term Provisions: 94700000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Long Term Provisions: 94700000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Machinery Furniture Equipment: 173651100000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Machinery Furniture Equipment: 173651100000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Minority Interest: 3096500000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Minority Interest: 3096500000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Minority Interests: -292300000.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Minority Interests: 43700000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Net Business Purchase And Sale: -34051300000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Net Common Stock Issuance: -38000000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Net Foreign Currency Exchange Gain Loss: -7971000000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Net Income: 114794200000.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Income: 27140300000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Net Income Common Stockholders: 114794200000.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 27140300000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Net Income Continuous Operations: 115086500000.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: 27096060000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 114794200000.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 27140300000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 114794200000.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 27140300000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Net Income From Continuing Operations: 151188800000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Net Income Including Noncontrolling Interests: 115086500000.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: 27096600000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Net Interest Income: 5760900000.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Interest Income: -858900000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Net Investment Purchase And Sale: -51897300000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Net Issuance Payments Of Debt: 19118800000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Net Long Term Debt Issuance: 17919600000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Net Non Operating Interest Income Expense: 5760900000.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -858900000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Net PPE: 126373200000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Net PPE: 126373200000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Net PPE Purchase And Sale: -35132500000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Net Short Term Debt Issuance: 1199200000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Net Tangible Assets: 601908500000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 601908500000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Revenue: 3480400000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Revenue: 3480400000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Assets: 40464600000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Assets: 40464600000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Liabilities: 3780200000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 3780200000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 5027100000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 5027100000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Non Current Prepaid Assets: 10374400000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Non Current Prepaid Assets: 10374400000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Normalized EBITDA: 188484000000.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 44127000000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Normalized Income: 118257814000.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Normalized Income: 27140300000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Operating Cash Flow: 124191800000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Operating Income: 135948200000.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Operating Income: 27519800000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Operating Revenue: 582201100000.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Operating Revenue: 145597500000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Ordinary Shares Number: 2399334970.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 2399334970.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Other Cash Adjustment Outside Changein Cash: 1627300000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Current Assets: 667000000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 667000000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Current Liabilities: 8918500000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 8918500000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Equity Interest: 833301600000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Equity Interest: 833301600000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Intangible Assets: 135461600000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 135461600000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Other Non Cash Items: -5764100000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Non Current Assets: 4710000000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 4710000000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Non Current Liabilities: 6394200000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: 6394200000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Other Non Operating Income Expenses: 1011500000.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: 4585000000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Other Operating Expenses: 57605600000.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Other Operating Expenses: 53228400000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Payable: 20211200000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Payable: 20211200000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Properties: 111141100000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Properties: 111141100000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Receivables: -403300000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Receivables: -403300000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Short Term Investments: 240109500000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 240109500000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Other Special Charges: 11455300000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Payables: 93729000000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Payables: 93729000000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 10988600000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 10988600000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Prepaid Assets: 30102200000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Prepaid Assets: 30102200000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Pretax Income: 151188800000.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Pretax Income: 35513400000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Properties: 0.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Properties: 0.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Provisionand Write Offof Assets: 634100000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Purchase Of Business: -34051300000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Purchase Of Investment: -348869300000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Purchase Of PPE: -36093700000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Raw Materials: 43878000000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Raw Materials: 43878000000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Reconciled Cost Of Revenue: 131731400000.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 28010900000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Reconciled Depreciation: 29378500000.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 7754700000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Rent And Landing Fees: 994000000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Rent Expense Supplemental: 994000000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Repayment Of Debt: -34101900000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Repurchase Of Capital Stock: -38000000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Restricted Cash: 219500000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Restricted Cash: 219500000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Retained Earnings: 693546300000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Retained Earnings: 693546300000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Sale Of Business: 0.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Sale Of Investment: 296972000000.00
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Sale Of PPE: 961200000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Selling And Marketing Expense: 77482400000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Selling General And Administration: 114774100000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Share Issued: 2399334970.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Share Issued: 2399334970.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Special Income Charges: -13288600000.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Special Income Charges: 0.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Stockholders Equity: 835700900000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 835700900000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Tangible Book Value: 601908500000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 601908500000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Tax Effect Of Unusual Items: -1063986000.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Tax Provision: 35543600000.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Tax Provision: 8276740000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Tax Rate For Calcs: 0.24
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.23
SUNPHARMA.NS cash_flow (annual, 2026-03-31) — Taxes Refund Paid: -23139400000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Assets: 1087852200000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Assets: 1087852200000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Capitalization: 836013500000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 836013500000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Debt: 46273200000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Debt: 46273200000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Equity Gross Minority Interest: 838797400000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 838797400000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Total Expenses: 446252900000.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Total Expenses: 118077700000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Liabilities Net Minority Interest: 249054800000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 249054800000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Non Current Assets: 448940300000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 448940300000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 22834400000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 22834400000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Tax Payable: 13500400000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 13500400000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Total Unusual Items: -4527600000.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items: 0.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Total Unusual Items Excluding Goodwill: -4527600000.00
SUNPHARMA.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: 0.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Tradeand Other Payables Non Current: 128900000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Tradeand Other Payables Non Current: 128900000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Work In Process: 19125500000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Work In Process: 19125500000.00
SUNPHARMA.NS balance_sheet (annual, 2026-03-31) — Working Capital: 412691500000.00
SUNPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Working Capital: 412691500000.00
SUNPHARMA.NS income_statement (annual, 2026-03-31) — Write Off: 125000000.00
SUNS balance_sheet (annual, 2023-12-31) — Accounts Payable: 10000.00
SUNS balance_sheet (annual, 2023-12-31) — Accrued Interest Receivable: 0.00
SUNS balance_sheet (annual, 2023-12-31) — Additional Paid In Capital: 0.00
SUNS balance_sheet (annual, 2023-12-31) — Capital Stock: 0.00
SUNS balance_sheet (annual, 2023-12-31) — Cash And Cash Equivalents: 31244622.00
SUNS balance_sheet (annual, 2023-12-31) — Cash Cash Equivalents And Short Term Investments: 31244622.00
SUNS balance_sheet (annual, 2023-12-31) — Common Stock: 0.00
SUNS balance_sheet (annual, 2023-12-31) — Common Stock Equity: 31234622.00
SUNS balance_sheet (annual, 2023-12-31) — Current Accrued Expenses: 0.00
SUNS balance_sheet (annual, 2023-12-31) — Current Assets: 31244622.00
SUNS balance_sheet (annual, 2023-12-31) — Current Liabilities: 10000.00
SUNS balance_sheet (annual, 2023-12-31) — Dividends Payable: 0.00
SUNS balance_sheet (annual, 2023-12-31) — Interest Payable: 0.00
SUNS balance_sheet (annual, 2023-12-31) — Invested Capital: 31234622.00
SUNS balance_sheet (annual, 2023-12-31) — Line Of Credit: 0.00
SUNS balance_sheet (annual, 2023-12-31) — Loans Receivable: 0.00
SUNS balance_sheet (annual, 2023-12-31) — Net Tangible Assets: 31234622.00
SUNS balance_sheet (annual, 2023-12-31) — Ordinary Shares Number: 6889031.00
SUNS balance_sheet (annual, 2023-12-31) — Other Equity Interest: 31234622.00
SUNS balance_sheet (annual, 2023-12-31) — Payables: 10000.00
SUNS balance_sheet (annual, 2023-12-31) — Payables And Accrued Expenses: 10000.00
SUNS balance_sheet (annual, 2023-12-31) — Preferred Stock: 0.00
SUNS balance_sheet (annual, 2023-12-31) — Receivables: 0.00
SUNS balance_sheet (annual, 2023-12-31) — Retained Earnings: 0.00
SUNS balance_sheet (annual, 2023-12-31) — Share Issued: 6889031.00
SUNS balance_sheet (annual, 2023-12-31) — Stockholders Equity: 31234622.00
SUNS balance_sheet (annual, 2023-12-31) — Tangible Book Value: 31234622.00
SUNS balance_sheet (annual, 2023-12-31) — Total Assets: 31244622.00
SUNS balance_sheet (annual, 2023-12-31) — Total Capitalization: 31234622.00
SUNS balance_sheet (annual, 2023-12-31) — Total Equity Gross Minority Interest: 31234622.00
SUNS balance_sheet (annual, 2023-12-31) — Total Liabilities Net Minority Interest: 10000.00
SUNS balance_sheet (annual, 2023-12-31) — Total Non Current Assets: 0.00
SUNS balance_sheet (annual, 2023-12-31) — Total Non Current Liabilities Net Minority Interest: 0.00
SUNS balance_sheet (annual, 2023-12-31) — Working Capital: 31234622.00
SUNS income_statement (quarterly, 2024-09-30) — Other Income Expense: -422238.00
SUNS income_statement (quarterly, 2024-09-30) — Other Non Operating Income Expenses: -422238.00
SUNS income_statement (annual, 2024-12-31) — +Operating Expense: 2944728.00
SUNS income_statement (annual, 2024-12-31) — +Total Revenue: 10844718.00
SUNS balance_sheet (annual, 2024-12-31) — Accounts Payable: 357417.00
SUNS balance_sheet (annual, 2024-12-31) — Accrued Interest Receivable: 1118927.00
SUNS balance_sheet (annual, 2024-12-31) — Additional Paid In Capital: 115022034.00
SUNS income_statement (annual, 2024-12-31) — Basic Average Shares: 6800841.00
SUNS income_statement (annual, 2024-12-31) — Basic EPS: 1.01
SUNS cash_flow (annual, 2024-12-31) — Beginning Cash Position: 31244622.00
SUNS balance_sheet (annual, 2024-12-31) — Capital Stock: 70047.00
SUNS balance_sheet (annual, 2024-12-31) — Cash And Cash Equivalents: 184626770.00
SUNS balance_sheet (annual, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 184626770.00
SUNS cash_flow (annual, 2024-12-31) — Cash Dividends Paid: -1454333.00
SUNS cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Financing Activities: 276920526.00